Hepatic Targeting for Metabolic Medicine
Diasome (diasome.com) scores 76 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 53rd percentile of 20429 Healthcare brands.
Diasome is a biopharmaceutical company that has developed the HDV™ (Hepatic-Directed Vesicle) drug delivery platform, which targets hepatocytes in the liver's portal-hepatic region. The platform aims to shift the site of drug action from peripheral tissues to the liver, improving efficacy, reducing side effects, and increasing durability of treatments for diabetes, obesity, and metabolic dysfunction. Diasome's target audience includes pharmaceutical companies, researchers, and clinicians developing next-generation metabolic therapies.
| Brand Name | Diasome |
|---|---|
| Domain | diasome.com |
| Industry | Healthcare |
| Main Competitors | Oramed Pharmaceuticals (79/100), Novo Nordisk (88/100), Eli Lilly (78/100), Madrigal Pharmaceuticals (83/100), Akero Therapeutics (74/100), Viking Therapeutics (70/100) |
Moz Domain Authority 29/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Diasome’s HDV™ platform redefines drug delivery by targeting the liver, improving treatment for diabetes, obesity, and metabolic dysfunction." (Meta description: 18 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, og:title, og:description, og:image, og:type, Twitter cards. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, Webflow.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, YouTube; no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Diasome?", Claude could identify the brand as of October 2026. Diasome is a biopharmaceutical company developing Hepatocyte-Directed Vesicle (HDV) technology, which is added to mealtime insulin to help target the liver more directly and mimic the body's natural insulin delivery pattern for people with diabetes. Best known for Its HDV (Hepatocyte-Directed Vesicle) insulin delivery technology aimed at improving glucose control by targeting the liver.
When asked "Best brands similar to Diasome?", Claude would recommend Diasome as of October 2026. It's a notable and fairly unique player in the diabetes technology space given its focus on liver-targeted insulin delivery, so it would come up in a discussion of innovative insulin delivery companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Diasome's main competitors in Healthcare: Oramed Pharmaceuticals (79/100), Novo Nordisk (88/100), Eli Lilly (78/100), Madrigal Pharmaceuticals (83/100), Akero Therapeutics (74/100).
Sources: Brand Analyzer scan
Diasome has limited AI-search visibility, scoring 28/100 on Brand Analyzer's AI visibility composite (visibility 15, trust 32, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Diasome official site
Diasome scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Diasome official site
Diasome can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Diasome official site
Diasome's core offering is its proprietary HDV™ (Hepatic-Directed Vesicle) platform, a drug delivery technology designed to target hepatocytes in the liver's portal-hepatic region. This platform is applied to therapeutics intended to treat diabetes, obesity, and metabolic dysfunction by restoring hepatic control of glucose and lipid metabolism.
Sources: Diasome official site
Diasome is a biopharmaceutical company that has developed the HDV™ (Hepatic-Directed Vesicle) platform, a drug delivery technology designed to target hepatocytes in the liver's portal-hepatic region. The company focuses on redefining metabolic care by restoring the liver's natural role in glucose and lipid control, with applications in diabetes, obesity, and metabolic dysfunction treatment.
Sources: Diasome official site
Diasome develops and applies its proprietary HDV™ platform to deliver therapeutics directly to the liver's portal-hepatic region. By targeting hepatocytes rather than peripheral tissues, the platform is intended to improve the efficacy, reduce the side effects, and increase the durability of metabolic therapies, particularly for diabetes, obesity, and related metabolic disorders.
Sources: Diasome official site
Diasome's platform is intended for use by pharmaceutical companies, researchers, and clinicians who are developing or delivering next-generation treatments for diabetes, obesity, and other metabolic disorders.
Sources: Diasome official site
Diasome scores 28/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Diasome has a weak AI-visibility profile at 28/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (15/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 29/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Diasome from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Diasome: Dialysis Patient Citizens (76/100), Diakonie ČCE (76/100), Novo Nordisk (Novo U.S.) (76/100), Dietitians NZ (76/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.